Lower radiation, same punch: new combo aims to tame rare lymphoma
NCT ID NCT07554482
First seen May 02, 2026 · Last updated May 05, 2026 · Updated 1 time
Summary
This study tests whether adding the drug selinexor to a lower dose of radiation can treat early-stage NK/T-cell lymphoma as effectively as standard high-dose radiation, but with fewer side effects. About 34 adults with untreated stage I-II disease will receive chemotherapy first, then selinexor plus 40 Gy radiation. The goal is to see if this approach can control the disease while reducing mouth sores and dry mouth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTRANODAL NK T CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tongren Hospital, Capital Medical University
Beijing, 100730, China
Conditions
Explore the condition pages connected to this study.